Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C18H27NO2 |
| Molecular Weight | 289.4125 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2
InChI
InChIKey=BZEWSEKUUPWQDQ-UHFFFAOYSA-N
InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3
| Molecular Formula | C18H27NO2 |
| Molecular Weight | 289.4125 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/14375392/Curator's Comment: Description was created based on several sources, including
http://www.sucrets.com/sore-throat-remedies | https://www.ncbi.nlm.nih.gov/pubmed/25113747 | https://www.drugs.com/monograph/dyclonine-hydrochloride.html | https://www.ncbi.nlm.nih.gov/pubmed/19148544 | https://www.ncbi.nlm.nih.gov/pubmed/25174315 | https://www.ncbi.nlm.nih.gov/pubmed/25113747
Sources: https://www.ncbi.nlm.nih.gov/pubmed/14375392/
Curator's Comment: Description was created based on several sources, including
http://www.sucrets.com/sore-throat-remedies | https://www.ncbi.nlm.nih.gov/pubmed/25113747 | https://www.drugs.com/monograph/dyclonine-hydrochloride.html | https://www.ncbi.nlm.nih.gov/pubmed/19148544 | https://www.ncbi.nlm.nih.gov/pubmed/25174315 | https://www.ncbi.nlm.nih.gov/pubmed/25113747
Dyclonine is an local anesthetic used to provide topical anesthesia to mucous membranes through sodium channel inhibition. It is the active ingredient in Sucrets, an over-the-counter throat lozenge. It has been used as a local anesthetic agent prior to laryngoscopy, bronchoscopy, esophagoscopy, or endotracheal intubation. However, oral solutions no longer are commercially available in the US. Recently, additional activities of dyclonine have been discovered. Dyclonine represents a novel therapeutic strategy that can potentially be repurposed for the treatment of Friedreich's ataxia. Dyclonine enhances the cytotoxic effect of proteasome inhibitors on cancer and multiple myeloma cells.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL4187 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25113747 |
6.0 µM [IC50] | ||
Target ID: CHEMBL6032 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25113747 |
|||
Target ID: CHEMBL1075094 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25113747 |
|||
Target ID: CHEMBL3578 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22021038 |
76.0 µM [IC50] | ||
Target ID: CHEMBL1935 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22021038 |
35.0 µM [IC50] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | SUCRETS Approved Usetemporarily relieves:
occasional minor irritation, pain, sore throat and sore mouth
cough associated with a cold or inhaled irritants |
|||
| Primary | Unknown Approved UseUnknown |
|||
| Primary | DYCLONE Approved UseHas been used as a local anesthetic agent prior to laryngoscopy, bronchoscopy, esophagoscopy, or endotracheal intubation. However, oral solutions no longer are commercially available in the US. |
|||
| Primary | Unknown Approved UseUnknown |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
42.17 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305084/ |
20 μg/cm² single, topical dose: 20 μg/cm² route of administration: Topical experiment type: SINGLE co-administered: |
DYCLONINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
152.81 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305084/ |
20 μg/cm² single, topical dose: 20 μg/cm² route of administration: Topical experiment type: SINGLE co-administered: |
DYCLONINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
5.85 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/22305084/ |
20 μg/cm² single, topical dose: 20 μg/cm² route of administration: Topical experiment type: SINGLE co-administered: |
DYCLONINE plasma | Rattus norvegicus population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Profiling of a prescription drug library for potential renal drug-drug interactions mediated by the organic cation transporter 2. | 2011-07-14 |
|
| Microneedle pretreatment improves efficacy of cutaneous topical anesthesia. | 2010-02 |
|
| Functional toxicogenomics: mechanism-centered toxicology. | 2010 |
|
| Best drugs for what ails you: the brands to buy--and those to skip. | 2009-09 |
|
| Dyclonine and alverine citrate enhance the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells. | 2009-02 |
|
| [The use of 1% dyclonine and local cryoanesthesia plus pulp vitality test agent in taking dental X-ray film]. | 2008-02 |
|
| Genome-wide fitness test and mechanism-of-action studies of inhibitory compounds in Candida albicans. | 2007-06 |
|
| Lidocaine exerts its effect on induced bronchospasm by mitigating reflexes, rather than by attenuation of smooth muscle contraction. | 2007-03 |
|
| Solid-state characterization of falicaine hydrochloride and isomorphic dyclonine hydrochloride. Part IV. Crystal polymorphism of local anaesthetic drugs. | 2004-12-20 |
|
| Chemical genomics in yeast. | 2004 |
|
| The uses of genome-wide yeast mutant collections. | 2004 |
|
| Both local anesthetics and salbutamol pretreatment affect reflex bronchoconstriction in volunteers with asthma undergoing awake fiberoptic intubation. | 2002-12 |
|
| Enigmatic pain referred to the teeth and jaws. | 2002-05-15 |
|
| Airway anesthesia alone does not explain attenuation of histamine-induced bronchospasm by local anesthetics: a comparison of lidocaine, ropivacaine, and dyclonine. | 2001-03 |
|
| Applications of microarray technology in breast cancer research. | 2001 |
Patents
Sample Use Guides
Oral/Throat Pain
1 lozenge (1.2, 2, or 3 mg); repeat after 2 hours if necessary
Usual Dosage
Use the lowest dose needed to provide effective anesthesia
Mouth sores: 5-10 mL of 0.5% or 1% to oral mucosa (swab or swish and then spit) 3-4 times/day as needed; maximum single dose: 200 mg (40 mL of 0.5% solution or 20 mL of 1% solution)
Bronchoscopy: Use 2 mL of the 1% solution or 4 mL of the 0.5% solution sprayed onto the larynx and trachea every 5 minutes until the reflex has been abolished
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19148544
Dyclonine enhances the cytotoxic effects of proteasome inhibitor MG132 on breast cancer cells in low micromolar range
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:45:12 GMT 2025
by
admin
on
Mon Mar 31 17:45:12 GMT 2025
|
| Record UNII |
078A24Q30O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C245
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
||
|
WHO-VATC |
QR02AD04
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
||
|
WHO-ATC |
N01BX02
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
||
|
WHO-VATC |
QN01BX02
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
||
|
WHO-ATC |
R02AD04
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
974
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
Dyclonine
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
3180
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
C29015
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
640
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
SUB06432MIG
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
DTXSID6047864
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
DYCLONINE
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
100000080480
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
4724
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
23744
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | RxNorm | ||
|
7173
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
586-60-7
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
078A24Q30O
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
m4790
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | Merck Index | ||
|
C100063
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201217
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
078A24Q30O
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY | |||
|
DB00645
Created by
admin on Mon Mar 31 17:45:12 GMT 2025 , Edited by admin on Mon Mar 31 17:45:12 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |